Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology
04 oct. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
CloudMedx Working With UCSF to Deploy AI Tools to Support the Management of Liver Cancer Patients Awaiting Liver Transplant
02 août 2018 17h21 HE
|
CloudMedx Inc.
PALO ALTO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- CloudMedx, a healthcare AI company that provides real time and actionable insights to the healthcare industry, today announced it is working with...
CELSION ANNOUNCES PUBLICATION OF THERMODOX® PHASE I CLINICAL STUDY RESULTS IN THE LANCET ONCOLOGY
10 juil. 2018 08h00 HE
|
Celsion CORP
– The TARDOX Study, in Collaboration with University of Oxford, Evaluates the Use of Focused Ultrasound in Combination with ThermoDox® to Treat Primary and Metastatic Liver Cancer – – Imaging...
Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
20 oct. 2017 08h30 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Raj...
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017
25 sept. 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced Peter G. Traber, M.D., the...
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
03 mai 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., May 03, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver...
Galectin Therapeutics Issues Statement Regarding GALTW and GALTU
23 mars 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., March 23, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that trading will be...
Surefire Receives Regulatory Approval for Infusion Systems and Guiding Catheters in Mexico
20 mars 2017 06h00 HE
|
Surefire Medical, Inc.
WESTMINSTER, Colo., March 20, 2017 (GLOBE NEWSWIRE) -- Surefire Medical, Inc., the developer of site-specific delivery devices for the Interventional Oncology market, announced today that the...
Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer
08 mars 2017 06h00 HE
|
Surefire Medical, Inc.
Study presented at SIR 2017 Annual Scientific Meeting WASHINGTON, March 08, 2017 (GLOBE NEWSWIRE) -- Surefire Medical, Inc. today announced that clinical data presented at the Society for...
Surefire Medical Launches New Flexion Guiding Catheter with Nitinol Tip for Better Shape Retention, Improved Back-up Support
06 mars 2017 06h00 HE
|
Surefire Medical, Inc.
WASHINGTON, March 06, 2017 (GLOBE NEWSWIRE) -- Surefire Medical, Inc. today announced the launch of the new Flexion Guiding Catheter at the Society for Interventional Radiology (SIR) meeting in...